axis

Galactose-{alpha}-1,3-galactose and Delayed Anaphylaxis, Angioedema, and Urticaria in Children

Delayed anaphylaxis, urticaria, and angioedema to mammalian meat products were first described in the adult population in 2009. Patients with this syndrome who consume mammalian meat typically develop symptoms 4 to 6 hours after ingestion.

Specific diagnoses for children who develop urticaria, angioedema, and idiopathic anaphylaxis are few and far between. We have now shown delayed anaphylaxis, urticaria, and angioedema due to mammalian meat products in the pediatric population. (Read the full article)




axis

Maternal Influence on Child HPA Axis: A Prospective Study of Cortisol Levels in Hair

Stress affects health of children, potentially persisting as a trajectory into adulthood. Earlier biological markers assess only momentary stress, making it difficult to investigate stress over longer periods of time. Cortisol in hair is a new biomarker of prolonged stress.

Mother and child hair cortisol association suggests a heritable part or maternal calibration. Cortisol output gradually stabilizes, has a stable trait, and is positively correlated to birth weight. Hair cortisol is a promising noninvasive biomarker of prolonged stress, especially applicable for children. (Read the full article)




axis

Effect of Palivizumab Prophylaxis on Subsequent Recurrent Wheezing in Preterm Infants

Palivizumab prophylaxis prevents respiratory syncytial virus lower respiratory tract infection. An association between respiratory syncytial virus infection and subsequent recurrent wheezing has been suggested by many studies. Only a few studies conducted from Europe and North America have addressed this causal association.

In a prospective, multicenter, case-control study of 440 children with high follow-up rate of 98.4%, palivizumab prophylaxis administered to preterm Japanese infants (33–35 weeks’ gestational age) in their first respiratory season reduced the incidence of subsequent recurrent wheezing up to 3 years. (Read the full article)




axis

Respiratory Syncytial Virus Prophylaxis in Down Syndrome: A Prospective Cohort Study

Down syndrome is an independent risk factor for severe respiratory syncytial virus infection and subsequent hospitalization.

This observational study suggests that immunoprophylaxis may reduce respiratory syncytial virus-related hospitalization by 3.6-fold (95% confidence interval, 1.5–8.7) in children with Down syndrome overall. (Read the full article)




axis

Clinical Practice Guideline: Nosebleed (Epistaxis)




axis

Axis Bank Q4 net loss at Rs 1,388 crore

The private sector lender had reported a net profit of Rs? 1,505.06 crore in the same quarter of the previous financial year.




axis

Axis Bank sets aside Rs 3,000 crore for COVID-19 impact

The bank’s advances grew 15% y-o-y to Rs 5,71,424 crore as on March 31, with retail loans up 24% y-o-y to Rs 3.05 lakh crore, accounting for 53% of the net advances.




axis

SBI vs HDFC vs ICICI vs Axis Bank: Where to get cheapest home loan? Rates compared

The marginal cost lending rate cut by banks and finance companies is good news for home loan and car loan borrowers whose loans are linked to MCLR. With the rate cut, all loans including home loans, auto loans, personal loans, etc., tied to the MCLR will become cheaper.




axis

Eastern Cape MEC for Health Alarmed As Taxis Bring 80 COVID-19-Positive Farmworkers Home From the Western Cape

[Daily Maverick] The Eastern Cape Department of Health has confirmed that 80 of a group of 188 seasonal farmworkers who returned to the province from the Western Cape over the past two weeks have tested positive for coronavirus. The taxis were 'intercepted' on the province's back roads near Elliotdale. Some drivers were allegedly in possession of fake permits. The positive test results come as nearly 10,000 people returned home during the window period allowed for interprovincial travel.




axis

Axis Bank| করোনা! ১৩৮৮ কোটি টাকা ক্ষতি অ্যাক্সিস ব্যাঙ্কের




axis

Dissimilarity of the gut-lung axis and dysbiosis of the lower airways in ventilated preterm infants

Background

Chronic lung disease of prematurity (CLD), also called bronchopulmonary dysplasia, is a major consequence of preterm birth, but the role of the microbiome in its development remains unclear. Therefore, we assessed the progression of the bacterial community in ventilated preterm infants over time in the upper and lower airways, and assessed the gut–lung axis by comparing bacterial communities in the upper and lower airways with stool findings. Finally, we assessed whether the bacterial communities were associated with lung inflammation to suggest dysbiosis.

Methods

We serially sampled multiple anatomical sites including the upper airway (nasopharyngeal aspirates), lower airways (tracheal aspirate fluid and bronchoalveolar lavage fluid) and the gut (stool) of ventilated preterm-born infants. Bacterial DNA load was measured in all samples and sequenced using the V3–V4 region of the 16S rRNA gene.

Results

From 1102 (539 nasopharyngeal aspirates, 276 tracheal aspirate fluid, 89 bronchoalveolar lavage, 198 stool) samples from 55 preterm infants, 352 (32%) amplified suitably for 16S RNA gene sequencing. Bacterial load was low at birth and quickly increased with time, but was associated with predominant operational taxonomic units (OTUs) in all sample types. There was dissimilarity in bacterial communities between the upper and lower airways and the gut, with a separate dysbiotic inflammatory process occurring in the lower airways of infants. Individual OTUs were associated with increased inflammatory markers.

Conclusions

Taken together, these findings suggest that targeted treatment of the predominant organisms, including those not routinely treated, such as Ureaplasma spp., may decrease the development of CLD in preterm-born infants.




axis

Long Noncoding RNA NRAV Promotes Respiratory Syncytial Virus Replication by Targeting the MicroRNA miR-509-3p/Rab5c Axis To Regulate Vesicle Transportation [Virus-Cell Interactions]

Respiratory syncytial virus (RSV) is an enveloped RNA virus which is responsible for approximately 80% of lower respiratory tract infections in children. Current lines of evidence have supported the functional involvement of long noncoding RNA (lncRNA) in many viral infectious diseases. However, the overall biological effect and clinical role of lncRNAs in RSV infection remain unclear. In this study, lncRNAs related to respiratory virus infection were obtained from the lncRNA database, and we collected 144 clinical sputum specimens to identify lncRNAs related to RSV infection. Quantitative PCR (qPCR) detection indicated that the expression of lncRNA negative regulator of antiviral response (NRAV) in RSV-positive patients was significantly lower than that in uninfected patients, but lncRNA psoriasis-associated non-protein coding RNA induced by stress (PRINS), nuclear paraspeckle assembly transcript 1 (NEAT1), and Nettoie Salmonella pas Theiler’s (NeST) showed no difference in vivo and in vitro. Meanwhile, overexpression of NRAV promoted RSV proliferation in A549 and BEAS-2B cells, and vice versa, indicating that the downregulation of NRAV was part of the host antiviral defense. RNA fluorescent in situ hybridization (FISH) confirmed that NRAV was mainly located in the cytoplasm. Through RNA sequencing, we found that Rab5c, which is a vesicle transporting protein, showed the same change trend as NRAV. Subsequent investigation revealed that NRAV was able to favor RSV production indirectly by sponging microRNA miR-509-3p so as to release Rab5c and facilitate vesicle transportation. The study provides a new insight into virus-host interaction through noncoding RNA, which may contribute to exploring potential antivirus targets for respiratory virus.

IMPORTANCE The mechanism of interaction between RSV and host noncoding RNAs is not fully understood. In this study, we found that the expression of long noncoding RNA (lncRNA) negative regulator of antiviral response (NRAV) was reduced in RSV-infected patients, and overexpression of NRAV facilitated RSV production in vitro, suggesting that the reduction of NRAV in RSV infection was part of the host antiviral response. We also found that NRAV competed with vesicle protein Rab5c for microRNA miR509-3p in cytoplasm to promote RSV vesicle transport and accelerate RSV proliferation, thereby improving our understanding of the pathogenic mechanism of RSV infection.




axis

NRF3-POMP-20S Proteasome Assembly Axis Promotes Cancer Development via Ubiquitin-Independent Proteolysis of p53 and Retinoblastoma Protein [Research Article]

Proteasomes are essential protease complexes that maintain cellular homeostasis, and aberrant proteasomal activity supports cancer development. The regulatory mechanisms and biological function of the ubiquitin-26S proteasome have been studied extensively, while those of the ubiquitin-independent 20S proteasome system remain obscure. Here, we show that the cap ’n’ collar (CNC) family transcription factor NRF3 specifically enhances 20S proteasome assembly in cancer cells and that 20S proteasomes contribute to colorectal cancer development through ubiquitin-independent proteolysis of the tumor suppressor p53 and retinoblastoma (Rb) proteins. The NRF3 gene is highly expressed in many cancer tissues and cell lines and is important for cancer cell growth. In cancer cells, NRF3 upregulates the assembly of the 20S proteasome by directly inducing the gene expression of the 20S proteasome maturation protein POMP. Interestingly, NRF3 knockdown not only increases p53 and Rb protein levels but also increases p53 activities for tumor suppression, including cell cycle arrest and induction of apoptosis. Furthermore, protein stability and cell viability assays using two distinct proteasome inhibitor anticancer drugs, the 20S proteasome inhibitor bortezomib and the ubiquitin-activating enzyme E1 inhibitor TAK-243, show that the upregulation of the NRF3-POMP axis leads to ubiquitin-independent proteolysis of p53 and Rb and to impaired sensitivity to bortezomib but not TAK-243. More importantly, the NRF3-POMP axis supports tumorigenesis and metastasis, with higher NRF3/POMP expression levels correlating with poor prognoses in patients with colorectal or rectal adenocarcinoma. These results suggest that the NRF3-POMP-20S proteasome assembly axis is significant for cancer development via ubiquitin-independent proteolysis of tumor suppressor proteins.




axis

E2F6-Mediated Downregulation of MIR22HG Facilitates the Progression of Laryngocarcinoma by Targeting the miR-5000-3p/FBXW7 Axis [Research Article]

Recently, abundant evidence has clarified that long noncoding RNAs (lncRNAs) play an oncogenic or anticancer role in the tumorigenesis and development of diverse human cancers. Described as a crucial regulator in some cancers, MIR22HG has not yet been studied in laryngocarcinoma and therefore the underlying regulatory role of MIR22HG in laryngocarcinoma is worth detecting. In this study, MIR22HG expression in laryngocarcinoma cells was confirmed to be downregulated, and upregulated MIR22HG expression led to suppressive effects on laryngocarcinoma cell proliferation and migration. Molecular mechanism assays revealed that MIR22HG sponges miR-5000-3p in laryngocarcinoma cells. Besides, decreased expression of miR-5000-3p suppressed laryngocarcinoma cell proliferation and migration. Moreover, the FBXW7 gene was reported to be a downstream target gene of miR-5000-3p in laryngocarcinoma cells. More importantly, rescue assays verified that FBXW7 depletion or miR-5000-3p upregulation countervailed the repressive effects of MIR22HG overexpression on laryngocarcinoma progression. In addition, E2F6 was proved to be capable of inhibiting MIR22HG transcription in laryngocarcinoma cells. To sum up, E2F6-induced downregulation of MIR22HG promotes laryngocarcinoma progression through the miR-5000-3p/FBXW7 axis.




axis

The tethering function of mitofusin2 controls osteoclast differentiation by modulating the Ca2+-NFATc1 axis [A2;A22]

Dynamic regulation of the mitochondrial network by mitofusins (MFNs) modulates energy production, cell survival, and many intracellular signaling events, including calcium handling. However, the relative importance of specific mitochondrial functions and their dependence on MFNs vary greatly among cell types. Osteoclasts have many mitochondria, and increased mitochondrial biogenesis and oxidative phosphorylation enhance bone resorption, but little is known about the mitochondrial network or MFNs in osteoclasts. Because expression of each MFN isoform increases with osteoclastogenesis, we conditionally deleted MFN1 and MFN2 (double conditional KO (dcKO)) in murine osteoclast precursors, finding that this increased bone mass in young female mice and abolished osteoclast precursor differentiation into mature osteoclasts in vitro. Defective osteoclastogenesis was reversed by overexpression of MFN2 but not MFN1; therefore, we generated mice lacking only MFN2 in osteoclasts. MFN2-deficient female mice had increased bone mass at 1 year and resistance to Receptor Activator of NF-κB Ligand (RANKL)-induced osteolysis at 8 weeks. To explore whether MFN-mediated tethering or mitophagy is important for osteoclastogenesis, we overexpressed MFN2 variants defective in either function in dcKO precursors and found that, although mitophagy was dispensable for differentiation, tethering was required. Because the master osteoclastogenic transcriptional regulator nuclear factor of activated T cells 1 (NFATc1) is calcium-regulated, we assessed calcium release from the endoplasmic reticulum and store-operated calcium entry and found that the latter was blunted in dcKO cells. Restored osteoclast differentiation by expression of intact MFN2 or the mitophagy-defective variant was associated with normalization of store-operated calcium entry and NFATc1 levels, indicating that MFN2 controls mitochondrion–endoplasmic reticulum tethering in osteoclasts.




axis

Two-Way Short Message Service (SMS) Communication May Increase Pre-Exposure Prophylaxis Continuation and Adherence Among Pregnant and Postpartum Women in Kenya

ABSTRACTIntroduction:We evaluated a 2-way short message service (SMS) communication platform to improve continuation of pre-exposure prophylaxis (PrEP) for HIV prevention among Kenyan women who initiated PrEP within routine maternal child health (MCH) and family planning clinics.Methods:We adapted an existing SMS platform (Mobile WACh [mWACh]) to send PrEP-tailored, theory-based SMS and allow clients to communicate with a remote nurse. Women who did not have HIV and who were initiating PrEP at 2 MCH/family planning clinics in Kisumu County, Kenya, from February to October 2018, were offered enrollment into the mWACh-PrEP program; SMS communication was free. We evaluated acceptability, satisfaction, and implementation metrics. In a pre/postevaluation, we compared PrEP continuation at 1-month postinitiation among women who initiated PrEP in the period before (n=166) versus after mWACh-PrEP implementation, adjusting for baseline differences.Results:Of the 334 women who were screened for enrollment into the mWACh-PrEP program; 193 (58%) were eligible and of those, 190 (98%) accepted enrollment. Reasons for ineligibility (n=141) included no phone access (29%) and shared SIM cards (25%). Median age was 25 years (interquartile range=22–30), and 91% were MCH clients. Compared to women who initiated PrEP in the month before mWACh-PrEP implementation, women who enrolled in mWACh-PrEP were more likely to return for their first PrEP follow-up visit (40% vs. 53%; adjusted risk ratio [aRR]=1.26; 95% confidence interval [CI]= 1.06, 1.50; P=.008) and more likely to continue PrEP (22% vs. 43%; aRR=1.75; 95% CI=1.21, 2.55; P=.003). Among those who returned, 99% reported successful receipt of SMS through the mWACh-PrEP system and 94% reported that mWACh-PrEP helped them understand PrEP better. Concerns about PrEP use, how it works, and side effects accounted for the majority (80%) of issues raised by participants using SMS.Conclusions:Two-way SMS expanded support for PrEP and opportunities for dialogue beyond the clinic and enabled women to ask and receive answers in real time regarding PrEP, which facilitated its continued use.




axis

Identification of a miR-146b-Fas ligand axis in the development of neutropenia in T large granular lymphocyte leukemia

Tlarge granular lymphocyte leukemia (T-LGLL) is characterized by the expansion of several large granular lymphocyte clones, among which a subset of large granular lymphocytes showing constitutively activated STAT3, a specific CD8+/CD4 phenotype and the presence of neutropenia has been identified. Although STAT3 is an inducer of transcription of a large number of oncogenes, so far its relationship with miRNAs has not been evaluated in T-LGLL patients. Here, we investigated whether STAT3 could carry out its pathogenetic role in T-LGLL through an altered expression of miRNAs. The expression level of 756 mature miRNA was assessed on purified T large granular lymphocytes (T-LGLs) by using a TaqMan Human microRNA Array. Hierarchical Clustering Analysis of miRNA array data shows that the global miRNome clusters with CD8 T-LGLs. Remarkably, CD8 T-LGLs exhibit a selective and STAT3-dependent repression of miR-146b expression, that significantly correlated with the absolute neutrophil counts and inversely correlated with the expression of Fas ligand (FasL), that is regarded as the most relevant factor in the pathogenesis of neutropenia. Experimental evidence demonstrates that the STAT3-dependent reduction of miR-146b expression in CD8 T-LGLs occurs as a consequence of miR-146b promoter hypermethylation and results in the disruption of the HuR-mediated post-transcriptional machinery controlling FasL mRNA stabilization. Restoring miR-146b expression in CD8 T-LGLs lead to a reduction of HuR protein and, in turn, of FasL mRNA expression, thus providing mechanistic insights for the existence of a STAT3-miR146b-FasL axis and neutropenia in T-LGLL.




axis

Uranus: The Planet on a Very Tilted Axis

Uranus is the seventh planet from the sun and sits on an axial plane tilted at a jaw-dropping 97.7-degree angle. And yes, Uranus does actually stink.




axis

Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs

The genetic mutations that cause epilepsy don’t stop there. Praxis Precision Medicines CEO Marcio Souza says research also links these genes to other neurological conditions. The biotech startup is turning that research into new neuro drugs and it’s coming out of stealth to share details about its science and its pipeline, which already has two […]




axis

Sunlight exposure and its role in skin-gut axis

Outside influences have shown strong correlations with what lives inside our bodies, and researchers are just beginning to understand how these environmental factors may affect the makeup of the gut microbiome.




axis

Adipogenesis of skeletal muscle fibro/adipogenic progenitors is affected by the WNT5a/GSK3/β-catenin axis




axis

The β-catenin/TCF-4-LINC01278-miR-1258-Smad2/3 axis promotes hepatocellular carcinoma metastasis




axis

The HMGB1-RAGE axis modulates the growth of autophagy-deficient hepatic tumors




axis

French startup will put 'flying' electric water taxis to work in Paris

It's like Uber for 'flying' water cars, with an über-cute name: SeaBubbles.




axis

Will driverless taxis kill public transit?

In Ottawa, Canada, self-driving cars are being touted as a reason to delay transit investment.




axis

Axis Equity Advantage Fund - Series 2 - Regular Plan - Growth Option

Category Growth
NAV 11.32
Repurchase Price
Sale Price
Date 08-May-2020




axis

Axis Equity Advantage Fund - Series 2 - Direct Plan - Growth Option

Category Growth
NAV 11.76
Repurchase Price
Sale Price
Date 08-May-2020




axis

Axis Equity Advantage Fund - Series 1 - Regular Plan - Growth Option

Category Growth
NAV 11.14
Repurchase Price
Sale Price
Date 08-May-2020




axis

Axis Equity Advantage Fund - Series 1 - Direct Plan - Growth Option

Category Growth
NAV 11.60
Repurchase Price
Sale Price
Date 08-May-2020




axis

Axis Emerging Opportunities Fund - Series 2 (1400 Days) - Regular Plan - Growth Option

Category Growth
NAV 10.19
Repurchase Price
Sale Price
Date 08-May-2020




axis

Axis Emerging Opportunities Fund - Series 2 (1400 Days) - Regular Plan - Dividend Option

Category Growth
NAV 9.16
Repurchase Price
Sale Price
Date 08-May-2020




axis

Axis Emerging Opportunities Fund - Series 2 (1400 Days) - Direct Plan - Growth Option

Category Growth
NAV 10.63
Repurchase Price
Sale Price
Date 08-May-2020




axis

Axis Emerging Opportunities Fund - Series 2 (1400 Days) - Direct Plan - Dividend Option

Category Growth
NAV 9.56
Repurchase Price
Sale Price
Date 08-May-2020




axis

Axis Emerging Opportunities Fund - Series 1 (1400 Days) - Regular Plan - Growth Option

Category Growth
NAV 10.68
Repurchase Price
Sale Price
Date 08-May-2020




axis

Axis Emerging Opportunities Fund - Series 1 (1400 Days) - Regular Plan - Dividend Option

Category Growth
NAV 8.98
Repurchase Price
Sale Price
Date 08-May-2020




axis

Axis Emerging Opportunities Fund - Series 1 (1400 Days) - Direct Plan - Growth Option

Category Growth
NAV 11.17
Repurchase Price
Sale Price
Date 08-May-2020




axis

Axis Emerging Opportunities Fund - Series 1 (1400 Days) - Direct Plan - Dividend Option

Category Growth
NAV 9.23
Repurchase Price
Sale Price
Date 08-May-2020




axis

Axis Capital Builder Fund - Series 4 (1582 Days) - Regular Plan - Growth Option

Category Growth
NAV 9.28
Repurchase Price
Sale Price
Date 08-May-2020




axis

Axis Capital Builder Fund - Series 4 (1582 Days) - Regular Plan - Dividend Option

Category Growth
NAV 9.28
Repurchase Price
Sale Price
Date 08-May-2020




axis

Axis Capital Builder Fund - Series 4 (1582 Days) - Direct Plan - Growth Option

Category Growth
NAV 9.41
Repurchase Price
Sale Price
Date 08-May-2020




axis

Axis Capital Builder Fund - Series 4 (1582 Days) - Direct Plan - Dividend Option

Category Growth
NAV 9.46
Repurchase Price
Sale Price
Date 08-May-2020




axis

Axis Capital Builder Fund - Series 1 (1540 Days) - Regular Plan - Growth option

Category Growth
NAV 8.90
Repurchase Price
Sale Price
Date 08-May-2020




axis

Axis Capital Builder Fund - Series 1 (1540 Days) - Regular Plan - Dividend option

Category Growth
NAV 8.90
Repurchase Price
Sale Price
Date 08-May-2020




axis

Axis Capital Builder Fund - Series 1 (1540 Days) - Direct Plan - Growth option

Category Growth
NAV 9.13
Repurchase Price
Sale Price
Date 08-May-2020




axis

Axis Capital Builder Fund - Series 1 (1540 Days) - Direct Plan - Dividend option

Category Growth
NAV 9.13
Repurchase Price
Sale Price
Date 08-May-2020




axis

Axis Hybrid Fund - Series 7 (1305 Days) - Regular Plan - Growth

Category Income
NAV 14.0922
Repurchase Price
Sale Price
Date 08-May-2020




axis

Axis Hybrid Fund - Series 7 (1305 Days) - Regular Plan - Dividend

Category Income
NAV 12.7404
Repurchase Price 12.7404
Sale Price 12.7404
Date 06-Mar-2017




axis

Axis Hybrid Fund - Series 7 (1305 Days) - Direct Plan -Dividend

Category Income
NAV 13.1752
Repurchase Price 13.1752
Sale Price 13.1752
Date 06-Mar-2017




axis

Axis Hybrid Fund - Series 7 (1305 Day) - Direct Plan - Growth

Category Income
NAV 13.1877
Repurchase Price 13.1877
Sale Price 13.1877
Date 06-Mar-2017




axis

Axis Hybrid Fund Series 6 (1324 Days) - Regular - Growth

Category Income
NAV 14.0916
Repurchase Price
Sale Price
Date 08-May-2020